Tesamorelin (Research Overview)
Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH) carrying an N-terminal trans-3-hexenoic acid group. It is used in research as a tool compound for studying GHRH receptor signaling and the growth hormone axis.
Mechanism of Action
Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, a Gs-coupled receptor that raises intracellular cAMP and drives growth hormone synthesis and release in receptor-signaling models. The trans-3-hexenoyl modification at the N-terminus is described in the literature as protecting the peptide from DPP-IV cleavage, which extends its stability compared with native GHRH.
Because it acts upstream at the pituitary, studies have examined how Tesamorelin preserves a pulsatile pattern of growth hormone release and how this differs from direct exposure to growth hormone itself. Downstream readouts commonly include IGF-1 levels in the models studied.
Research Areas
Published research has examined the GH–IGF-1 axis in cell-based receptor assays and in animal models, using Tesamorelin to characterize GHRH receptor pharmacology, receptor desensitization, and feedback signaling.
A separate body of published clinical-literature work has reported on body-composition and metabolic endpoints in defined study populations. These reports are summarized for context only and are not claims about any product we sell.
Findings from animal or in-vitro systems do not establish safety or efficacy for any indication and should not be interpreted as medical claims.
Specification summary
Tesamorelin
Stated purity ≥99%. For laboratory research use only.
Related materials
References
- Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304. PMID 20554713 · DOI
- Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID 31611038 · DOI
- Wang Y, Tomlinson B. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opin Investig Drugs. 2009;18(3):303-10. PMID 19243281 · DOI
- Halmos G, Szabo Z, Juhasz E, Schally AV. Signaling mechanism of growth hormone-releasing hormone receptor. Vitam Horm. 2023;123:1-26. PMID 37717982 · DOI
Cited literature is provided for scientific context only and does not describe or endorse any use of these products.
For laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.